Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461577 | PMC |
| http://dx.doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_191_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Broad Differential Diagnoses in a Case of Catatonia Secondary to Clozapine Withdrawal.
Prim Care Companion CNS Disord
January 2025
Department of Psychiatry, Maimonides Medical Center, Brooklyn, New York.
Maintenance treatment of catatonia with benzodiazepines: A case series and literature review.
Neuropsychopharmacol Hung
December 2024
College of Medicine, University of Kentucky, Lexington, KY 40506, USA.
Objective: Benzodiazepines, particularly lorazepam, are good options for acute catatonia treatment. Published catatonia literature on benzodiazepine maintenance treatment and benzodiazepine tolerance is limited.
Methods: This is a chart review covering 30 years of clinical experience in the state of Kentucky, (United States of America), where there was no easy access to electroconvulsive therapy.
Clozapine-Associated Sialorrhea: A Literature Review.
J Clin Psychopharmacol
October 2024
TOBB University of Economics and Technology, Faculty of Medicine, Ankara, Turkey.
Background: Clozapine has demonstrated efficacy in treating treatment-resistant schizophrenia; however, it has a wide range of side effects. Sialorrhea is a common side effect of clozapine that causes the patient to withdraw from social life. This review aims to evaluate and summarize the prevalence, mechanism, risk factors, and management of clozapine-associated sialorrhea.
View Article and Find Full Text PDFGenetic identification of undiagnosed benign ethnic neutropenia in patients receiving clozapine treatment.
Br J Psychiatry
December 2024
Institute of Pharmaceutical Sciences, King's College London, UK; and Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.
Article Synopsis
- Clozapine therapy can lead to agranulocytosis, which requires monitoring of white blood cell counts, and it's crucial to identify benign ethnic neutropenia (BEN) to avoid unnecessary clozapine withdrawal.
- * A study introduced voluntary genetic testing for BEN in a clozapine clinic to determine how many patients had undiagnosed BEN, finding that 24% of participants were newly diagnosed with this condition.
- * Results showed that undiagnosed BEN was common among patients, suggesting that adding genetic testing to regular monitoring could improve clozapine therapy management and enable safe continuation for those with unrecognized BEN.
Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety.
Patient Prefer Adherence
November 2024
Mental Health Research Center, Eastern State Hospital, Lexington, KY, USA.
Purpose: Clozapine is an antipsychotic which was approved in 1989 for treatment-resistant schizophrenia in the United States (US). There were few randomized trials before its approval and potentially lethal clozapine adverse drug reactions (ADRs), such as agranulocytosis and myocarditis were identified by pharmacovigilance. VigiBase, the WHO global database, is a cornerstone of international pharmacovigilance efforts for ADR identification during post-marketing surveillance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!